Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Melanoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1

Interventions

Imatinib Mesylate 23Cyclophosphamide 18fludarabine 17fludarabine phosphate 13Busulfan 12Whole-Body Irradiation 11nilotinib 10Dasatinib 9thymoglobulin 8ponatinib 8Mycophenolic Acid 8Cytarabine 7Antilymphocyte Serum 7peginterferon alfa-2b 6Tacrolimus 6Cyclosporine 6Clofarabine 6Thiotepa 5Stem Cell Transplantation 4Sirolimus 4Rituximab 4Peripheral Blood Stem Cell Transplantation 4Melphalan 4Alemtuzumab 4sargramostim 3Interferon-alpha 3Homoharringtonine 3Cord Blood Stem Cell Transplantation 3Bortezomib 3zileuton 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Protein Subunit Vaccines × Clear all
NCT00415857 2018-08-21

Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)

M.D. Anderson Cancer Center

Phase 2 Terminated
5 enrolled 3 charts
MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡